The Ministry of Health intends to begin administering doses in 2026, free of charge, through the SUS, the country’s national heal care network.
In a statement, Anvisa reported that the publication makes official the conclusion of the regulatory process and enables the production and sale of the vaccine, which will be offered exclusively through the public health system.
“The registration is a milestone in the fight against dengue in Brazil. The vaccine has undergone all the technical and regulatory stages required by health legislation, ensuring its safety, quality, and efficacy,” the text reads.








